IBDEI227 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,32868,0)
 ;;=H35.3121^^128^1671^8
 ;;^UTILITY(U,$J,358.3,32868,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32868,1,3,0)
 ;;=3^NonEx AMD,OS,Early Dry Stage
 ;;^UTILITY(U,$J,358.3,32868,1,4,0)
 ;;=4^H35.3121
 ;;^UTILITY(U,$J,358.3,32868,2)
 ;;=^5138506
 ;;^UTILITY(U,$J,358.3,32869,0)
 ;;=H35.3122^^128^1671^9
 ;;^UTILITY(U,$J,358.3,32869,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32869,1,3,0)
 ;;=3^NonEx AMD,OS,Intermed Dry Stage
 ;;^UTILITY(U,$J,358.3,32869,1,4,0)
 ;;=4^H35.3122
 ;;^UTILITY(U,$J,358.3,32869,2)
 ;;=^5138507
 ;;^UTILITY(U,$J,358.3,32870,0)
 ;;=H35.3123^^128^1671^10
 ;;^UTILITY(U,$J,358.3,32870,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32870,1,3,0)
 ;;=3^NonEx AMD,OS,Adv Atrpc w/o Sbfvl Invlv
 ;;^UTILITY(U,$J,358.3,32870,1,4,0)
 ;;=4^H35.3123
 ;;^UTILITY(U,$J,358.3,32870,2)
 ;;=^5138508
 ;;^UTILITY(U,$J,358.3,32871,0)
 ;;=H35.3124^^128^1671^11
 ;;^UTILITY(U,$J,358.3,32871,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32871,1,3,0)
 ;;=3^NonEx AMD,OS,Adv Atrpc w/ Sbfvl Invlv
 ;;^UTILITY(U,$J,358.3,32871,1,4,0)
 ;;=4^H35.3124
 ;;^UTILITY(U,$J,358.3,32871,2)
 ;;=^5138509
 ;;^UTILITY(U,$J,358.3,32872,0)
 ;;=H35.3110^^128^1671^2
 ;;^UTILITY(U,$J,358.3,32872,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32872,1,3,0)
 ;;=3^NonEx AMD,OD,Stage Unspec
 ;;^UTILITY(U,$J,358.3,32872,1,4,0)
 ;;=4^H35.3110
 ;;^UTILITY(U,$J,358.3,32872,2)
 ;;=^5138500
 ;;^UTILITY(U,$J,358.3,32873,0)
 ;;=H35.3111^^128^1671^3
 ;;^UTILITY(U,$J,358.3,32873,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32873,1,3,0)
 ;;=3^NonEx AMD,OD,Early Dry Stage
 ;;^UTILITY(U,$J,358.3,32873,1,4,0)
 ;;=4^H35.3111
 ;;^UTILITY(U,$J,358.3,32873,2)
 ;;=^5138501
 ;;^UTILITY(U,$J,358.3,32874,0)
 ;;=H35.3112^^128^1671^4
 ;;^UTILITY(U,$J,358.3,32874,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32874,1,3,0)
 ;;=3^NonEx AMD,OD,Intermed Dry Stage
 ;;^UTILITY(U,$J,358.3,32874,1,4,0)
 ;;=4^H35.3112
 ;;^UTILITY(U,$J,358.3,32874,2)
 ;;=^5138502
 ;;^UTILITY(U,$J,358.3,32875,0)
 ;;=H35.3113^^128^1671^5
 ;;^UTILITY(U,$J,358.3,32875,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32875,1,3,0)
 ;;=3^NonEx AMD,OD,Adv Atrpc w/o Sbfvl Invlv
 ;;^UTILITY(U,$J,358.3,32875,1,4,0)
 ;;=4^H35.3113
 ;;^UTILITY(U,$J,358.3,32875,2)
 ;;=^5138503
 ;;^UTILITY(U,$J,358.3,32876,0)
 ;;=H35.3114^^128^1671^6
 ;;^UTILITY(U,$J,358.3,32876,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32876,1,3,0)
 ;;=3^NonEx AMD,OD,Adv Atrpc w/ Subfvl Invlv
 ;;^UTILITY(U,$J,358.3,32876,1,4,0)
 ;;=4^H35.3114
 ;;^UTILITY(U,$J,358.3,32876,2)
 ;;=^5138504
 ;;^UTILITY(U,$J,358.3,32877,0)
 ;;=H32.^^128^1672^12
 ;;^UTILITY(U,$J,358.3,32877,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32877,1,3,0)
 ;;=3^Chorioretinal Disorders,Secondary,Unspec
 ;;^UTILITY(U,$J,358.3,32877,1,4,0)
 ;;=4^H32.
 ;;^UTILITY(U,$J,358.3,32877,2)
 ;;=^5005489
 ;;^UTILITY(U,$J,358.3,32878,0)
 ;;=H30.93^^128^1672^11
 ;;^UTILITY(U,$J,358.3,32878,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32878,1,3,0)
 ;;=3^Chorioretinal Inflammation,Unspec,OU
 ;;^UTILITY(U,$J,358.3,32878,1,4,0)
 ;;=4^H30.93
 ;;^UTILITY(U,$J,358.3,32878,2)
 ;;=^5005435
 ;;^UTILITY(U,$J,358.3,32879,0)
 ;;=H30.91^^128^1672^9
 ;;^UTILITY(U,$J,358.3,32879,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,32879,1,3,0)
 ;;=3^Chorioretinal Inflammation,Unspec,OD
 ;;^UTILITY(U,$J,358.3,32879,1,4,0)
 ;;=4^H30.91
 ;;^UTILITY(U,$J,358.3,32879,2)
 ;;=^5133481
